Navigation Links
New drug to multiple sclerosis symptoms

A new drug AVP-923 is all set to provide relief to people suffering from the dreaded disease of multiple// sclerosis, said the researchers from University of Vermont College of Medicine, US.

Multiple sclerosis is a chronic neurological disease of the central nervous system. The disease affects the brain and spinal cord and medication till date had only been able to treat the problem symptomatically. One of the symptoms of this disease is called pseudobulbar affect is often characterized by episodes of laughter and crying in inappropriate situations. The outbursts are often spontaneous and the patients may have very little control over the expressions.

The new drug will be helping the patients to control much of their inappropriate emotional outbursts. The patients who were given the drug in the clinical trial had also reported of improvement in their quality of life, interpersonal relationships and physical comfort and pain. One of the side effects of the drug was reported to be spells of dizziness.

This is the first drug designed to specifically treat the condition of pseudobulbar affect in patients with multiple sclerosis. The results of the study was presented at the American Academy of Neurology 57th Annual Meeting, held on April 9-16.

Reference: American Academy of Neurology 57th Annual Meeting, Press Release
'"/>




Page: 1

Related medicine news :

1. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
2. Associated therapy for multiple myeloma
3. Latest drug shows promise in multiple myeloma
4. Vitamin D to reduce multiple sclerosis
5. Smoking may affect multiple sclerosis
6. Low immunity in people with multiple sclerosis may be genetical
7. Thalidomide is the new approved drug for treating multiple cancers
8. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
9. Calcium-blocker delays atherosclerosis than beta-blockers
10. Adult stem cells in treatment for Multiple sclerosis (MS)
11. Vitamin D to reduce multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug multiple sclerosis symptoms

(Date:7/8/2008)... SKINTASTIC™ is p...ed Evolence®--the latest injectable collagen f...owntime beauty treatments. EVOLENCE® utilizes ...as a preferred medical grafting substance due to i... , N. Dallas/Plano, TX (PR...
(Date:7/8/2008)... HARRISBURG, Pa., July 8 /PRNewswire-USNewswire...ecutive order regarding the Pennsylvania Health,Ca...fter the law,authorizing its operation expired on ...hen PHC4 was allowed to "sunset",by the General As...ction., The Rendell administration is committed t...
(Date:7/8/2008)...,This new executive team will give the men we serv..., said Carl J. Bentley, President, M.I. Board of ...July 8 /PRNewswire/ -- The Mariners Inn shelter an...ng the appointment of Jim Hartz as,chief executive...cer., "Both Jim and David are outstanding leaders...
(Date:7/8/2008)... Reductions in Iron Blood Levels Associated with...rial Disease , Men with peripheral arterial dis...rial in which their iron stores were reduced by bl...tive to men in the trial who did not undergo blood... that lower levels of iron in the blood may be ass...
Breaking Medicine News(10 mins):Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 3Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Mariners Inn Announces New Executive Leadership 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4
...o seek counseling and undergo screening for HIV, a... of Health has reported.// It is estimated that n...ing services since 2000, thanks to the awareness i...to ascertain their status. In 2005/06, nearly 1.7-...
...d Family Welfare stressed the urgency to focus on ... a country //where nearly 5.2 million people are s... 600 million youth under risk. It must be noted t...ases are reported from rural India, of which 40% h...
...es to step up vigilance following an outbreak of b...re ministry.// South Korea Tuesday reported its s...as well as pigs and dogs culled. Heilongjiang, Ji...angsu and Zhejiang provinces are all relatively cl...
...ist Neurological Institute (NI) are studying the u... gene therapy to treat typically// stubborn malign...diation and gene therapy, has already proven succe...e cancer. Methodist is one of only two sites in th...
Other Medicine News:
(Date:7/7/2008)... ATLANTA, July 7 /- GeoV...ta based, publicly traded biopharmaceutical,compan...infectious,diseases, today provided an operational... Phase 2 preventative human clinical trial testing...s with its AIDS vaccine. Five,successful human tri...
(Date:7/7/2008)... CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall...d today that it has had discussions with the Food,...ceptable patient,population for a new clinical tri...ne)], or HBOC-201. Biopure has proposed to study u...elogenous Leukemia (AML) who refuse,transfusion wi...
(Date:7/7/2008)... New Study Suggests Kiwifruit is Top Perfo... Not all fruits are created equal when,it comes to...s among the,highest in bioavailability compared to...cent small-scale study published in the Journal of... include vitamins and phytochemicals called flavon...
(Date:7/6/2008)... Results are basis for CTI,s Marketing Authorizati...der review by the EMEA, SEATTLE, July 7 /PRNewswi...sdaq: CTIC ; MTA) today announced the publication...mparing OPAXIO(TM) (paclitaxel poliglumex,CT-2103...t of PS 2,(performance status 2) patients with pre...
Breaking Medicine Technology:GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5Biopure Announces Meeting With FDA 2Biopure Announces Meeting With FDA 3Kiwifruit: Antioxidant Power in Quantity and Quality 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5A study proposes a new universal rule to explain the equilibrium of plant populations 433 1A study proposes a new universal rule to explain the equilibrium of plant populations 433 2Old at Age 3 3A The Inspiring Life of Progeria Patient Zachary Moore 1460 1Old at Age 3 3A The Inspiring Life of Progeria Patient Zachary Moore 1460 2Old at Age 3 3A The Inspiring Life of Progeria Patient Zachary Moore 1460 3Old at Age 3 3A The Inspiring Life of Progeria Patient Zachary Moore 1460 4GlaxoSmithKline Awarded U S Department of Defense Contract to Pursue Novel Antibacterial Research Program 645 1GlaxoSmithKline Awarded U S Department of Defense Contract to Pursue Novel Antibacterial Research Program 645 2GlaxoSmithKline Awarded U S Department of Defense Contract to Pursue Novel Antibacterial Research Program 645 3Premier Research Appoints Global Head of Human Resources 642 1Premier Research Appoints Global Head of Human Resources 642 2
...IRE)--May 22, 2007 - Medtronic,(NYSE:MDT) today pr...cal trial program reinforcing the existing safety ...ng coronary stent system.,Four-year results from t...hree-year results from the nearly 1,200 patient EN...iated with sustained,safety, significant reduction...
...ox Maintained Stability,Significantly Longer than ...le Comparable with Placebo , MARIETTA, Ga. and COL...als, Inc., Wyeth Pharmaceuticals, a division of Wy...l study results on,bifeprunox, an investigational ...phrenia, today at the 2007 annual meeting of,the A...
Other Medicine Technology:Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 2Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: